AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer

AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer

Shots:

  • The P-III POSEIDON study involves assessing of Imfinzi + platinum-based CT or Imfinzi + Tremelimumab + CT vs CT as monothx as a 1L treatment in patients with non-squamous or squamous mNSCLC with all PD-L1 expression levels
  • The P-III POSEIDON study resulted in meeting its 1EPs & 2EPs i.e, improvement in final PFS analysis in patients treated with Imfinzi + SoC platinum-based CT & improvement in PFS in patients treated with triple regimen respectively
  • Imfinzi is a mAb targeting PD-L1, blocking the interaction of PD-L1 with PD-1 and CD80 with its anticipated additional 1EPs of OS data in 2020 while Tremelimumab is a mAb targeting the activity CTLA-4, contributing to T cell activation and boosting the immune response to cancer

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Hindustan Times